Status:
COMPLETED
Evaluation of PK and Safety of D-0120 and Allopurinol
Lead Sponsor:
InventisBio Co., Ltd
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
EARLY_PHASE1
Brief Summary
Evaluation of safety and PK interaction between D-0120 and Alopurinol in healthy adult subjects
Eligibility Criteria
Inclusion
- Healthy subjects between the ages of 18-55
- Required evaluation by Investigator for screening and enrollment
- Agreement and compliance with the study and follow-up procedures
Exclusion
- Significant medical history or current comorbidly determined by the Investigator.
- Pregnant or nursing women
Key Trial Info
Start Date :
November 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 23 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05360628
Start Date
November 1 2021
End Date
July 23 2022
Last Update
March 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Spaulding Clinical
West Bend, Wisconsin, United States, 53095